Ablynx replaces CSO with Robert Friesen

24 January 2018

Belgian biotech firm Ablynx (Euronext Brussels: ABLX) today announced the appointment of Robert Friesen as chief scientific officer (CSO), effective March 1, 2018.

Dr Friesen will lead the company’s scientific, research and technology activities and become a member of the executive committee. He succeeds Dr Antonin de Fougerolles, Ablynx’ previous CSO, who left the company last year to become chief executive at Evox Therapeutics.

Dr Friesen has more than 20 years of experience in the biopharmaceutical industry, leading multiple R&D organizations. He joins Ablynx from ProQR Therapeutics, a clinical-stage biotechnology company, where he is currently senior vice president, heading the science and early development division. Prior to joining ProQR Therapeutics, Dr Friesen worked at Janssen BioTherapeutics, a Johnson & Johnson company as global head of biologics research, where he established an efficient R&D organization of more than 200 scientists and professionals located in Europe and US; and at the Crucell Vaccine Institute, also a J&J company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK